← Leaderboards
Shuxin Li
Ut Southwestern Medical Center
$8,564,717
Attributed
$9,428,340
Total exposure
7
Grants
7
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.3M · FY2010–25$2M$1.5M$1M$500K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,428,340 · 7
By mechanism
R01$8,996,427 · 6
R21$431,913 · 1
Top collaborators
- Yimin Zou5 shared
Most similar at Ut Southwestern Medical Center
Same institution · by research overlap
- Kevin Kyung Park$6,854,716
- Angelique Wright Whitehurst$6,833,234
- Chun-Li Zhang$16,071,777
Others in their field
Top investigators on “Neurons”
- Hongkui Zeng · Allen Institute$106,358,289
- Eric Martin McDade · Washington University$94,632,845
- Ed Lein · Allen Institute$90,858,363
- Randall J Bateman · Washington University$65,841,935
- John Morris · Washington University$65,018,684
- Paul S. Aisen · Cognition Therapeutics, Inc.$58,570,460
Research focus
NeuronsRodentAxonGrowthCentral Nervous System InjuryAxon GrowthNatural RegenerationSignal TransductionAxon RegenerationAdultMolecular TargetPeptidesMediatingDesignRecoveryRecovery Of FunctionFailureCicatrixPathway InteractionsIn VivoChondroitin Sulfate ProteoglycanLocomotor RecoveryEnvironmentRepaired
Grant awards (27)
Identifying novel regenerative treatments for CNS injury in adult mammals$499,013
R01 · FY2025 · NS · contact PI
Bioengineering of highly effective AAV vectors for noninvasive gene delivery to the nervous system$356,625
R01 · FY2025 · NS · contact PI
Identifying novel regenerative treatments for CNS injury in adult mammals$484,043
R01 · FY2024 · NS · contact PI
Bioengineering of highly effective AAV vectors for noninvasive gene delivery to the nervous system$384,363
R01 · FY2024 · NS · contact PI
Identifying novel regenerative treatments for CNS injury in adult mammals$499,013
R01 · FY2023 · NS · contact PI
Bioengineering of highly effective AAV vectors for noninvasive gene delivery to the nervous system$396,250
R01 · FY2023 · NS · contact PI
VRC: Develop regenerative therapies for neurological vision loss$378,709
R01 · FY2023 · EY · contact PI
Bioengineering of highly effective AAV vectors for noninvasive gene delivery to the nervous system$396,250
R01 · FY2022 · NS · contact PI
VRC: Develop regenerative therapies for neurological vision loss$375,981
R01 · FY2022 · EY · contact PI
Develop a combinatorial therapy for spinal cord injury$342,890
R01 · FY2022 · NS · contact PI
VRC: Develop regenerative therapies for neurological vision loss$396,250
R01 · FY2021 · EY · contact PI
Develop a combinatorial therapy for spinal cord injury$342,890
R01 · FY2021 · NS · contact PI
Develop a combinatorial therapy for spinal cord injury$342,890
R01 · FY2020 · NS · contact PI
Develop a combinatorial therapy for spinal cord injury$342,890
R01 · FY2019 · NS · contact PI
Develop a combinatorial therapy for spinal cord injury$355,687
R01 · FY2018 · NS · contact PI
CSPG receptors and PTEN in CNS regeneration$341,250
R01 · FY2018 · NS · contact PI
Therapeutic Strategies for Repairing Optic Nerve Injury$351,000
R01 · FY2017 · EY · contact PI
CSPG receptors and PTEN in CNS regeneration$341,250
R01 · FY2017 · NS · contact PI
Therapeutic Strategies for Repairing Optic Nerve Injury$351,000
R01 · FY2016 · EY · contact PI
CSPG receptors and PTEN in CNS regeneration$341,250
R01 · FY2016 · NS · contact PI
Therapeutic Strategies for Repairing Optic Nerve Injury$343,980
R01 · FY2015 · EY · contact PI
CSPG receptors and PTEN in CNS regeneration$341,250
R01 · FY2015 · NS · contact PI
Therapeutic Strategies for Repairing Optic Nerve Injury$351,000
R01 · FY2014 · EY · contact PI
CSPG receptors and PTEN in CNS regeneration$340,703
R01 · FY2014 · NS · contact PI
Overcoming glial scar inhibitions on axonal growth$129,918
R21 · FY2011 · NS · contact PI
Overcoming glial scar inhibitions on axonal growth$64,245
R21 · FY2011 · NS · contact PI
Overcoming glial scar inhibitions on axonal growth$237,750
R21 · FY2010 · NS · contact PI